Hi Neo, I've been playing around with numbers just like you and came with much the same conclusion and compelling story. I used the total number of oncology shares likely to be out there (excluding over allocation) i.e. 10,842,020m and then used $14 and $16 in Aussie dollars and came up with a total capitalisation of $173m and $152m respectively. I had current ACL holders share at 70% giving a value of $121m and $106m to the oncology asset and then subtracted that from the current capitalisation of ACL of 153m which then valued fonda at $32m (11.5 cents a share) or $47m (17cents a share). I have used the number of 280m as the total number of ACL shares for this calculation.
All sounds too good to be true!
- Forums
- ASX - By Stock
- TSN
- audeo indicative ipo pricing is now public
audeo indicative ipo pricing is now public, page-16
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online